World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment

Alessandro Villa, Andy Wolff, Doron Aframian, Arjan Vissink, Jörgen Ekström, Gordon Proctor, Richard McGowan, Nagamani Narayana, Ardita Aliko, Ying Wai Sia, Revan Kumar Joshi, Siri Beier Jensen, Alexander Ross Kerr, Colin Dawes, Anne Marie Lynge Pedersen

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Objectives: Medication-induced salivary gland dysfunction (MISGD) causes significant morbidity resulting in decreased quality of life. This systematic review assessed the literature on the prevalence, diagnosis, treatment, and prevention of MISGD. Materials and methods: Electronic databases were searched for articles related to MISGD through June 2013. Four independent reviewers extracted information regarding study design, study population, interventions, outcomes, and conclusions for each article. Only papers with acceptable degree of relevance, quality of methodology, and strength of evidence were retained for further analysis. Results: There were limited data on the epidemiology of MISGD. Furthermore, various methods were used to assess salivary flow rate or xerostomia. Preventive and therapeutic strategies included substitution of medications, oral, or systemic therapy with sialogogues, use of saliva substitutes or of electro-stimulating devices. Although there are promising approaches to improve salivary gland function, most studies are characterized by small numbers and heterogeneous methods. Conclusions: Physicians and dentists should identify the medications associated with xerostomia and salivary gland dysfunction through a thorough medical history. Preferably, health care providers should measure the unstimulated and stimulated whole salivary flow rates of all their patients so that these values can be used as a baseline to rate the complaints of patients who subsequently claim to experience xerostomia or salivary gland dysfunction as well as the possibilities of effectively treating this condition. Clinical relevance: MISGD remains a major burden for the population. This systematic review provides a contemporary in-depth description of the diagnosis and treatment of MISGD.

Original languageEnglish (US)
Pages (from-to)1563-1580
Number of pages18
JournalClinical Oral Investigations
Volume19
Issue number7
DOIs
StatePublished - Sep 19 2015

Fingerprint

Oral Medicine
Salivary Glands
Education
Xerostomia
Therapeutics
Dentists
Saliva
Health Personnel
Population
Epidemiology
Quality of Life
Databases
Morbidity
Physicians
Equipment and Supplies

Keywords

  • Medications
  • Saliva
  • Salivary gland dysfunction
  • Xerostomia

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

World Workshop on Oral Medicine VI : a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment. / Villa, Alessandro; Wolff, Andy; Aframian, Doron; Vissink, Arjan; Ekström, Jörgen; Proctor, Gordon; McGowan, Richard; Narayana, Nagamani; Aliko, Ardita; Sia, Ying Wai; Joshi, Revan Kumar; Jensen, Siri Beier; Kerr, Alexander Ross; Dawes, Colin; Pedersen, Anne Marie Lynge.

In: Clinical Oral Investigations, Vol. 19, No. 7, 19.09.2015, p. 1563-1580.

Research output: Contribution to journalReview article

Villa, A, Wolff, A, Aframian, D, Vissink, A, Ekström, J, Proctor, G, McGowan, R, Narayana, N, Aliko, A, Sia, YW, Joshi, RK, Jensen, SB, Kerr, AR, Dawes, C & Pedersen, AML 2015, 'World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment', Clinical Oral Investigations, vol. 19, no. 7, pp. 1563-1580. https://doi.org/10.1007/s00784-015-1488-2
Villa, Alessandro ; Wolff, Andy ; Aframian, Doron ; Vissink, Arjan ; Ekström, Jörgen ; Proctor, Gordon ; McGowan, Richard ; Narayana, Nagamani ; Aliko, Ardita ; Sia, Ying Wai ; Joshi, Revan Kumar ; Jensen, Siri Beier ; Kerr, Alexander Ross ; Dawes, Colin ; Pedersen, Anne Marie Lynge. / World Workshop on Oral Medicine VI : a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment. In: Clinical Oral Investigations. 2015 ; Vol. 19, No. 7. pp. 1563-1580.
@article{4af4579e4cd743eb8cb98cd5e2eaae1b,
title = "World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment",
abstract = "Objectives: Medication-induced salivary gland dysfunction (MISGD) causes significant morbidity resulting in decreased quality of life. This systematic review assessed the literature on the prevalence, diagnosis, treatment, and prevention of MISGD. Materials and methods: Electronic databases were searched for articles related to MISGD through June 2013. Four independent reviewers extracted information regarding study design, study population, interventions, outcomes, and conclusions for each article. Only papers with acceptable degree of relevance, quality of methodology, and strength of evidence were retained for further analysis. Results: There were limited data on the epidemiology of MISGD. Furthermore, various methods were used to assess salivary flow rate or xerostomia. Preventive and therapeutic strategies included substitution of medications, oral, or systemic therapy with sialogogues, use of saliva substitutes or of electro-stimulating devices. Although there are promising approaches to improve salivary gland function, most studies are characterized by small numbers and heterogeneous methods. Conclusions: Physicians and dentists should identify the medications associated with xerostomia and salivary gland dysfunction through a thorough medical history. Preferably, health care providers should measure the unstimulated and stimulated whole salivary flow rates of all their patients so that these values can be used as a baseline to rate the complaints of patients who subsequently claim to experience xerostomia or salivary gland dysfunction as well as the possibilities of effectively treating this condition. Clinical relevance: MISGD remains a major burden for the population. This systematic review provides a contemporary in-depth description of the diagnosis and treatment of MISGD.",
keywords = "Medications, Saliva, Salivary gland dysfunction, Xerostomia",
author = "Alessandro Villa and Andy Wolff and Doron Aframian and Arjan Vissink and J{\"o}rgen Ekstr{\"o}m and Gordon Proctor and Richard McGowan and Nagamani Narayana and Ardita Aliko and Sia, {Ying Wai} and Joshi, {Revan Kumar} and Jensen, {Siri Beier} and Kerr, {Alexander Ross} and Colin Dawes and Pedersen, {Anne Marie Lynge}",
year = "2015",
month = "9",
day = "19",
doi = "10.1007/s00784-015-1488-2",
language = "English (US)",
volume = "19",
pages = "1563--1580",
journal = "Clinical Oral Investigations",
issn = "1432-6981",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - World Workshop on Oral Medicine VI

T2 - a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment

AU - Villa, Alessandro

AU - Wolff, Andy

AU - Aframian, Doron

AU - Vissink, Arjan

AU - Ekström, Jörgen

AU - Proctor, Gordon

AU - McGowan, Richard

AU - Narayana, Nagamani

AU - Aliko, Ardita

AU - Sia, Ying Wai

AU - Joshi, Revan Kumar

AU - Jensen, Siri Beier

AU - Kerr, Alexander Ross

AU - Dawes, Colin

AU - Pedersen, Anne Marie Lynge

PY - 2015/9/19

Y1 - 2015/9/19

N2 - Objectives: Medication-induced salivary gland dysfunction (MISGD) causes significant morbidity resulting in decreased quality of life. This systematic review assessed the literature on the prevalence, diagnosis, treatment, and prevention of MISGD. Materials and methods: Electronic databases were searched for articles related to MISGD through June 2013. Four independent reviewers extracted information regarding study design, study population, interventions, outcomes, and conclusions for each article. Only papers with acceptable degree of relevance, quality of methodology, and strength of evidence were retained for further analysis. Results: There were limited data on the epidemiology of MISGD. Furthermore, various methods were used to assess salivary flow rate or xerostomia. Preventive and therapeutic strategies included substitution of medications, oral, or systemic therapy with sialogogues, use of saliva substitutes or of electro-stimulating devices. Although there are promising approaches to improve salivary gland function, most studies are characterized by small numbers and heterogeneous methods. Conclusions: Physicians and dentists should identify the medications associated with xerostomia and salivary gland dysfunction through a thorough medical history. Preferably, health care providers should measure the unstimulated and stimulated whole salivary flow rates of all their patients so that these values can be used as a baseline to rate the complaints of patients who subsequently claim to experience xerostomia or salivary gland dysfunction as well as the possibilities of effectively treating this condition. Clinical relevance: MISGD remains a major burden for the population. This systematic review provides a contemporary in-depth description of the diagnosis and treatment of MISGD.

AB - Objectives: Medication-induced salivary gland dysfunction (MISGD) causes significant morbidity resulting in decreased quality of life. This systematic review assessed the literature on the prevalence, diagnosis, treatment, and prevention of MISGD. Materials and methods: Electronic databases were searched for articles related to MISGD through June 2013. Four independent reviewers extracted information regarding study design, study population, interventions, outcomes, and conclusions for each article. Only papers with acceptable degree of relevance, quality of methodology, and strength of evidence were retained for further analysis. Results: There were limited data on the epidemiology of MISGD. Furthermore, various methods were used to assess salivary flow rate or xerostomia. Preventive and therapeutic strategies included substitution of medications, oral, or systemic therapy with sialogogues, use of saliva substitutes or of electro-stimulating devices. Although there are promising approaches to improve salivary gland function, most studies are characterized by small numbers and heterogeneous methods. Conclusions: Physicians and dentists should identify the medications associated with xerostomia and salivary gland dysfunction through a thorough medical history. Preferably, health care providers should measure the unstimulated and stimulated whole salivary flow rates of all their patients so that these values can be used as a baseline to rate the complaints of patients who subsequently claim to experience xerostomia or salivary gland dysfunction as well as the possibilities of effectively treating this condition. Clinical relevance: MISGD remains a major burden for the population. This systematic review provides a contemporary in-depth description of the diagnosis and treatment of MISGD.

KW - Medications

KW - Saliva

KW - Salivary gland dysfunction

KW - Xerostomia

UR - http://www.scopus.com/inward/record.url?scp=84939471885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939471885&partnerID=8YFLogxK

U2 - 10.1007/s00784-015-1488-2

DO - 10.1007/s00784-015-1488-2

M3 - Review article

C2 - 25994331

AN - SCOPUS:84939471885

VL - 19

SP - 1563

EP - 1580

JO - Clinical Oral Investigations

JF - Clinical Oral Investigations

SN - 1432-6981

IS - 7

ER -